Agios Pharmaceuticals (AGIO) TD Cowen 46th Annual Health Care Conference summary

Key milestones and strategic updates

• Approval and launch of mitapivat (PYRUKYND) for thalassemia marked a major milestone, with strong initial uptake and positive feedback from clinicians and payers.

• Ongoing regulatory engagement for sickle cell disease, with a pre-sNDA FDA meeting in Q1 and disclosure of the regulatory path expected after receipt of meeting minutes.

• Phase 2b data for tebapivat in lower-risk MDS expected in the first half of the year, with top-line results for sickle cell disease in the second half.

• Early-stage pipeline includes assets for polycythemia vera (phase 1) and phenylketonuria.

• Plans to expand mitapivat and other assets into pediatric populations for both thalassemia and sickle cell disease.

Clinical data and regulatory outlook

• RISE UP Phase 3 study in sickle cell disease met the hemoglobin improvement endpoint but not vaso-occlusive crisis reduction; responder analysis showed significant clinical benefits for a subset of patients.

• Safety profile for mitapivat in sickle cell disease is favorable, with no hepatocellular injury events seen as in thalassemia.

• FDA feedback will guide next steps for sickle cell disease filing; company awaits meeting minutes to determine strategic direction.

• Competitor data (etavopivat) expected in Q2, but will not alter current regulatory or commercial plans.

Commercial launch and market dynamics

• Strong initial launch for mitapivat in thalassemia, with 44 prescriptions in the first 4-5 weeks and broad label acceptance.

• Payer response has been positive, with no significant hurdles anticipated for patient access.

• Launch trajectory expected to be gradual, with early uptake among transfusion-dependent patients and longer-term growth driven by non-transfusion-dependent segment.

• U.S. market will be the primary revenue driver, with global opportunity estimated at $1 billion, mostly from thalassemia.

• Plans to match market penetration to prevalence distribution over several years, with equal focus on both transfusion-dependent and non-dependent patients.